



Citation for published version:

Milo, S, Nzakizwanayo, J, Hathaway, HJ, Jones, BV & Jenkins, ATA 2019, 'Emerging medical and engineering strategies for the prevention of long-term indwelling catheter blockage', Proceedings of the Institution of Mechanical Engineers, Part H - Journal of Engineering in Medicine, vol. 233, no. 1, pp. 68-83.
<https://doi.org/10.1177/0954411918776691>

DOI:

[10.1177/0954411918776691](https://doi.org/10.1177/0954411918776691)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](#)

Milo, S., Nzakizwanayo, J., Hathaway, H. J., Jones, B. V., & Jenkins, A. T. A. (2018). Emerging medical and engineering strategies for the prevention of long-term indwelling catheter blockage. Proceedings of the Institution of Mechanical Engineers, Part H - Journal of Engineering in Medicine. DOI: 10.1177/0954411918776691. Copyright © 2018 IMechE. Reprinted by permission of SAGE Publications.

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Emerging Medical and Engineering Strategies for the Prevention of Long-Term Indwelling Catheter Blockage

Scarlet Milo^{1*}, Jonathan Nzakizwanayo², Hollie J. Hathaway³, Brian V. Jones², A. Toby A. Jenkins¹

¹Department of Chemistry, University of Bath, BA2 7AY, UK

² School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, East Sussex, BN2 4GJ, UK

³ Department of Chemistry, Lancaster University, Lancaster, LA1 4YB, UK

Corresponding author: Scarlet Milo, Department of Chemistry, University of Bath, BA2 7AY, UK. Email: S.Milo@bath.ac.uk

Abstract

Urinary catheters have been used on an intermittent or indwelling basis for centuries, in order to relieve urinary retention and incontinence. Nevertheless, the use of urinary catheters in the clinical setting is fraught with complication, the most common of which is the development of nosocomial urinary tract infections (UTIs), known as catheter-associated urinary tract infections (CAUTIs). Infections of this nature are not only significant owing to their high incidence rate and subsequent economic burden, but also to the severe medical consequences that result. A range of techniques have been employed in recent years, utilising various technologies in attempts to counteract the perilous medical cascade following catheter blockage. This review will focus on the current advancement (within the last 10 years) in prevention of encrustation and blockage of long-term indwelling catheters both from engineering and medical perspectives, with particular emphasis on the importance of stimuli-responsive systems.

Keywords

Catheter-associated urinary tract infection, *Proteus mirabilis*, biofilm, hydrogel, bacteriophage

Introduction

The Clinical Problem: CAUTI

Of the approximately 100 million catheters sold annually worldwide,¹ the most commonly employed in the healthcare setting is the Foley indwelling urinary catheter, which constitutes a flexible silicone or latex tube (inserted into the bladder via the urethra), held in place by an inflatable balloon and connected to a drainage bag, thus completing the sterile closed-drainage system. In the UK alone, complications arising from the use of Foley catheters cost the National Health Service (NHS) between £1.0-2.5 billion, and accounts for approximately 2100 deaths annually.² CAUTIs constitute 80% of all nosocomial UTIs, thus comprising over 40% of all nosocomial infections in the USA alone.^{3,4}

1
2
3 Despite innate mechanical safeguards against microbial invasion of the urinary tract, specific
4 pathogens are capable of colonising and thriving in this environmental niche. Within the
5 healthy, uncatheterised urinary tract, the regular flushing of the urethra as a result of bladder
6 emptying helps to impede ascending infection of the urinary tract by mechanical means.⁵
7 Further biological safeguards such as the lining of the bladder with urothelial cells (covered
8 with a glycosaminoglycan mucin), also helps to mitigate infection by resisting adherence via
9 the activation of microbial-sensing proteins, thus triggering the host defences with a cascade
10 of cellular and molecular effectors.⁶ Catheterisation of the urinary tract provides opportunities
11 that may be exploited by uropathogenic species for avoidance of such safeguards, thus
12 resulting in successful colonisation and an increase in patient susceptibility to UTIs.⁷ The
13 majority of opportunistic uropathogens are faecal contaminants or skin residents from the
14 patient's own native or transitory microflora, originating in the periurethral area.^{8,9} Bacterial
15 entry into the bladder may occur at the point of catheterisation, through the catheter lumen, or
16 along the catheter-urethral interface.¹⁰ Approximately two thirds of bladder colonisation
17 during CAUTI occurs via the extraluminal route, where organisms ascend from the urethral
18 meatus, via the catheter/urethra interface. Less common is bladder colonisation via the
19 intraluminal route (approximately one third of CAUTI), where bacterial cells transfer into the
20 bladder as a result of manipulation of the sterile closed drainage system.^{11,12}

21
22 Catheter-associated bacteriuria (CAB) is defined as the presence of $\geq 10^5$ colony forming
23 units per millilitre (CFU/ml) of one or more bacterial species in a single catheter urine
24 sample. It is generally universal in patients undergoing long-term indwelling catheterization,
25 and is detected in the majority of patients who have been catheterised for > 1week.¹³
26 Fortunately, most cases of CAB are asymptomatic and are thus commonly referred to as
27 catheter-associated asymptomatic bacteriuria (CAASB). Antibiotic prophylaxis is not
28 recommended for CAASB, although it may postpone biofilm infections for 1-2 weeks.¹⁴
29 Indeed, the ECDPC recently reported that the most common isolates from CAUTI are
30 resistant to at least one of the antimicrobial agents commonly used in clinical practice.
31 Namely, 26.3% of *E. coli* isolates are resistant to third-generation cephalosporins, 26.6% of
32 *P. aeruginosa* isolates are resistant to ceftazidime, and 9.5% of *Enterococcus* sp. Isolated are
33 resistant to vancomycin.¹⁵

34
35 In contrast, the term CAUTI is used to refer to individuals suffering from symptomatic
36 infection that is significant bacteriuria as well of symptoms of infection in the absence of any
37 other identifiable sources. Although fewer than 3% of patients with CAASB develop
38 bacteraemia, given the prevalence of infections of this nature, CAUTI is one of the most
39 common causes of secondary bloodstream infection in acute care facilities. Additionally,
40 CAUTI is the source of over 50% of episodes of blood stream infections within the long-term
41 care setting.¹⁶

42 43 44 History and Development of the Foley Catheter

45
46 Derived from the ancient Greek *kathiénai*, the word *catheter* can be literally translated as “to
47 thrust into”, or “to send down”, and is used to describe an instrument used to drain fluid from
48 a body cavity. Since its initial inception into human medicine more than 3500 years ago, a
49 vast array of materials and designs have been employed to drain the dysfunctional bladder.
50 Early documentation reveals that metals (such as copper, tin, bronze and gold) were used by
51 the Greek physiologist Erasistratus in the third century B.C.¹⁷ Egyptians utilised lead and
52 papyrus in the design and manufacture of early catheter models,¹⁸ whilst the Chinese in 100
53 B.C. exploited organic materials such as palm leaves, dried reeds or hollow onion stems that
54 were lacquered as urological devices.¹⁹ The first example of a flexible catheter made of
55 malleable gum-elastic was created by Bernard (a French jeweller and goldsmith) in the late
56
57
58
59
60

1
2
3 18th century, following the development of natural rubber in 1735.¹⁷ Difficulties in achieving
4 a compromise between rigidity and flexibility were not overcome until the vulcanisation of
5 rubber was discovered by Charles Goodyear in 1839.¹⁹ The concept of a catheter retention
6 balloon was introduced in 1853, using rubber or woven fabric dipped in linseed oil and
7 baked.²⁰ The modern-day Foley catheter, used within the acute care and community settings
8 today, was first introduced in the mid-1930s by Dr. Frederick B. Foley.²¹ Despite being one
9 of the most commonly used medical devices employed within modern medicine, and the
10 cornerstone for the management of urinary incontinence, the Foley catheter has opened a
11 Pandora's Box of medical complications, owing to its inherent design flaws and vulnerability
12 to rapid-onset bacteriuria.⁵
13

14 Long Term Indwelling Catheters

15
16
17 Duration of catheterisation is the most important risk-factor associated with CAUTI.
18 Approximately 10-50% of patients undergoing short-term or intermittent catheterisation (1-7
19 days) develop bacteriuria, whereas catheterisation for >28 days **often results in the**
20 **development of CAUTI.**²² Encrustation and blockage following infection by *Proteus*
21 *mirabilis* (*P. mirabilis*) is a common complication associated with urinary devices, and is a
22 major cause of morbidity and mortality in CAUTI.²³
23

24 *Proteus mirabilis*: Pathogenesis and Mechanisms of Catheter

25 Encrustation

26
27

28 *P. mirabilis* are Gram-negative members of the family *Enterobacteriaceae*, distinguishable
29 from almost any other genera by their striking ability to swarm across a solid surface.²⁴
30 Indwelling urinary catheters serve as the ideal initiation site of infection by *P. mirabilis*. **This**
31 **pathogen has** been shown to have the greatest ability to attach to catheter surfaces **(including**
32 **ethylene, propylene, polystyrene, sulfonated polystyrene, silicone and red rubber catheters)**
33 **than any other Gram-negative organism.**^{24,25} **There is strong epidemiological and**
34 **experimental evidence that *P. mirabilis* is the major cause of catheter encrustation,**²⁶
35 **and has been found to colonise approximately 40% of all chronic indwelling catheters.**¹⁶
36

37 Within the catheterised urinary tract, **microorganisms not only live** as planktonic cultures of
38 dispersed single cells, but tend to accumulate at interfaces to form polymicrobial aggregates
39 known as biofilms. **Biofilms comprise communities of surface-attached cells**, embedded into
40 an extracellular polymeric matrix. Biofilm formation occurs as a result of complex intra- and
41 intercellular signalling and coordinated communication processes, mainly regulated by the
42 quorum sensing system ubiquitous in the bacterial world.^{3,27} Biofilms initially formed on the
43 catheter surface tend to be monomicrobial, although often develop into polymicrobial
44 structures during long-term catheterisation, with up to 72% of catheters being colonised by
45 two or more species,²⁸ including combinations of *P. mirabilis*, *Morganella morganii*,
46 *Providencia stuartii*, *Escherichia coli* (*E. coli*), *Pseudomonas aeruginosa* (*P. aeruginosa*) and
47 *Klebsiella pneumoniae*.²⁹⁻³¹
48

49 **Although *P. mirabilis* is generally not the first organism found to colonise the catheter**
50 **surface, it is common and of great significance in long-term catheterisation (Figure 1).**
51 **Indeed, the most frequent causative agent for UTI in humans (approximately 80%), and one**
52 **of the most common causes of Gram-negative bacteraemia in hospitalised patients is *E. coli*.**³
53 **The longer a catheter is in place, the more like it is to become colonized by *P. mirabilis*.**
54 **Since *P. mirabilis* biofilms are both more copious and more likely to cause blockage than**
55 **those of other species, the focus of this review will henceforth be on infection, biofilm**
56 **formation, and subsequent blockage of catheters following infection by this species in**
57
58
59
60

1
2
3 particular.¹⁶ *P. mirabilis* is able to express a wide variety of virulence factors, perhaps the
4 most relevant of which in terms of CAUTI initiation and establishment is the expression of a
5 potent urease enzyme; a cytoplasmic nickel metalloenzyme whose upregulation is initiated by
6 a shift to host body temperature and high concentrations of urea.^{32,33} Urease induces the
7 hydrolysis of urea to ammonia and carbon dioxide, thus elevating urinary pH and facilitating
8 the precipitation of polyvalent ions within the urine. The resultant formation of struvite
9 (magnesium ammonium phosphate) and apatite (calcium phosphate) crystals typically occurs
10 when the urine pH is elevated to 8.2,³⁴ and such crystals may then accumulate within the
11 biofilms on the external and luminal catheter surfaces, obstructing urine flow and leading to
12 complications such as incontinence and painful distention of the bladder (owing to urinary
13 retention). This in turn leads to severe sequelae such as vesicoureteral reflux, bacteriuria, and
14 ascending infection resulting in possible pyelonephritis and septicaemia.³⁰
15 Furthermore, *P. mirabilis* is capable of producing an arsenal of bacterial toxins, two of which
16 (haemolysin (HpmA) and *Proteus* toxic agglutinin (Pta), are involved in the process of tissue
17 damage and renal migration, thus inducing acute pyelonephritis.^{35,36} HpmA is a Ca²⁺-
18 dependent pore-forming cytolysin, which achieves destabilisation of the host cell by inserting
19 into the cell membrane, causing Na⁺ efflux. Pta is a surface-associated cytotoxic protease,
20 functional only at the high urinary pH consequential of *P. mirabilis* urease. It achieves
21 bladder and kidney damage via damage to the structural integrity of the native cells. In the
22 proposed mechanism of action, Pta punctures the host cell membrane, inducing cytosol
23 leakage, osmotic stress and depolymerisation of actin filaments.^{4,37}
24
25

26 [Insert Figure 1]
27

28 This review endeavors to present a range of novel approaches to biofilm reduction and
29 eradication. The emphasis is mainly on techniques that are not yet clinically tested, but
30 nevertheless have shown significant promise in lab-based trials for the application of
31 delay/prevention of catheter blockage following infection by *Proteus mirabilis*. Some
32 methods discussed may have not been utilized in the field of catheter encrustation to date,
33 although demonstrate many aspects of transferable technology which may prove useful for
34 the future of CAUTI management.
35
36

37 Part I: Engineering Approaches

38 Passive Release Coatings

39
40 Release-based coatings exert their antibacterial activity by leaching antibacterial compounds
41 over time, exposing and subsequently killing bacterial cells both adhered and planktonic. In
42 contrast to traditional methods of administering antibacterial agents, release coatings provide
43 the ability to deliver agents at a high local concentration, whilst limiting systemic exposure
44 and toxicity. Passive release of antimicrobial agents aims to achieve effective prophylaxis as
45 well as potential treatment of established bacteriuria, although the reservoirs of antimicrobial
46 cargos are inherently limited, thus their action is ultimately temporary. Unlike the stimuli-
47 responsive approaches discussed in Part III, passive release kinetic profiles generally follow
48 first- or second- order kinetics, where an initial burst release is followed by a decreasing tail
49 distribution.³⁸ The timeframe of the concentration decline is highly application-dependent,
50 although generally varies from hours to days, providing a significant challenge in coating
51 design, specifically compromising between medical device function and sufficient cargo
52 concentration within the carrier matrix. To date, the design of coatings that maintain
53
54
55
56
57
58
59
60

antimicrobial concentrations throughout the therapeutic window, sufficient to kill bacteria but low enough to limit eukaryotic cytotoxicity, remains a significant challenge.³⁹

Emerging Developments in Catheter Coatings

Over the past decade, imbuing or coating medical implants in antimicrobial solutions has been commonly used to control infection. A broad range of passive release-based systems have been explored for the prevention or delay of urinary catheter encrustation and blockage, the most common of which is simple impregnation, where the agent is held within a reservoir and released via diffusion. The lack of a specific bonding mechanism results in rapid liberation from the release matrix, which generally utilises a polymeric carrier, for example poly(methacrylic acid) (PMMA), poly(vinyl alcohol) (PVA), poly(acrylic acid) (PAA), or poly(lactic-*co*-glycolic acid) (PLGA).⁴⁰

Other approaches to achieve antimicrobial coatings on urinary catheters whilst avoiding the use of a polymeric reservoir include deposition by sonochemical methods. Shalom *et al*⁴¹ described the coating of urinary catheters with Zn-doped CuO nanoparticles using a high energy ultrasonic method, which displayed promising antibiofilm activity and biocompatibility as indicated by low *in vitro* cytotoxicity and negligible associated cytokine secretion. Evaluation of coated catheters *in vivo* using a rabbit model showed that rabbits catheterised with uncoated catheters scored positive for CAUTI after 4 days. In contrast, rabbits with coated catheters did not exhibit CAUTI until day 7 or remained uninfected for the entire duration of the 7-day experiment.

Nitric oxide (NO), a potent biofilm inhibitor, has also been exploited for use in indwelling medical devices.⁴²⁻⁴⁴ Colleta *et al*⁴⁵ has investigated the impregnation of commercially available silicone Foley catheters with S-nitroso-N-acetyl-D-penicillamine (SNAP) via solvent swelling. SNAP acts a synthetic NO donor, exhibiting long-term NO release and stability when incorporated into low-water uptake polymers. Cytotoxicity testing using a mouse fibroblast cell-line showed that SNAP-impregnated catheters were fully biocompatible, whilst assessment of prototype catheters against 3-day *P. mirabilis* biofilms showed a 3-logarithmic reduction in cell viability when compared with control catheter segments. SNAP-doped catheter tubing was able to substantially decrease bacterial viability at each stage of biofilm maturation, thus making it, at the time of writing, the first example of the use of a synthetic NO donor capable of preventing mature *P. mirabilis* biofilm formation, whilst producing stable NO at nontoxic fluxes.

Hydrogels

Hydrogel coatings have also been employed as drug delivery systems for the potential release of therapeutic agents from the catheter surface. Hydrogels are ubiquitous throughout the literature and widely accepted as being suitable carrier matrices for the delivery of antimicrobial compounds. Hydrogels are cross-linked, insoluble, hydrophilic polymer networks capable of entrapping significant volumes of water as their liquid component. Hydrophilic coating of catheters provides a number of advantages over standard silicone catheters, including reduced patient discomfort, increased lubricity and reduced encrustation as a result of decreased microbial cell adhesion at the tissue-biomaterial interface.^{46,13,47} Hydrogels have been shown to increase aggregation of planktonic cells and newly-nucleated crystals, leading to accelerated catheter blockage, although the addition of active agents is able to suppress this negative effect.⁴⁸

Recently, preparation of hyaluronic acid (HA)-based hydrogels crosslinked with poly(methyl vinyl ether-*alt*-maleic acid) by thermal and microwave processes were evaluated as drug delivery systems using methylene blue (MB) as a model drug. Synthesised hydrogels showed a high affinity for MB, and were capable of sustained release over a period of 48 hours.

1
2
3 Additionally, *in vitro* microbiological assessment of the HA-based hydrogels demonstrated
4 resistance to microbial adherence (greater than one-logarithmic reduction when compared
5 with a PVC control) when evaluated with representative nosocomial strains of
6 *Staphylococcus aureus* (*S. aureus*) and *P. mirabilis*.⁴⁹
7

8 Anti-Adhesion / Antifouling Approaches 9

10 Approaches designed to prevent adhesion of bacteria generally aim to impede biofilm
11 formation in its infancy using non-cytotoxic mechanisms (either by unfavourable surface
12 topography or surface chemistry). Bacterial adhesion to biomaterial surfaces such as urinary
13 catheters is generally described using a two stage model: initial, rapid, reversible adhesion
14 (stage 1), mediated by non-specific physicochemical interactions, followed by secondary
15 'locking' adhesion (stage 2) involving specific bacterial-adhesion proteins.⁵⁰ Since the host-
16 derived conditioning film of urinary components begins development upon insertion of the
17 Foley catheter, any existing surface properties of the material are often concealed, and
18 pathogen attachment promoted. Therefore, development of antifouling coatings must target
19 not only uropathogen attachment but urinary constituents as well. Whilst the conceptual
20 simplicity and potential biocompatibility of anti-adhesion coatings makes them an appealing
21 approach, their antibacterial action requires extremely close proximity with bacterial cells.
22 Surfaces such as catheters may become rapidly contaminated with non-specifically attached
23 materials or dead cells, thus compromising the defect-free surface. Consequently, large-scale
24 production and subsequent handling may prove challenging in future.
25
26

27 Poly(ethylene glycol) (PEG)-Based Approaches 28

29 The field of antifouling polymers is fast-growing, with new polymer structures being
30 frequently designed for this specific purpose.⁵¹ Poly(ethylene glycol) (PEG) has been the
31 most widely used polymer for antifouling in recent years,^{52,53} although its efficacy is
32 dependent upon the surface grafting technique and polymeric architecture.⁵⁴ Development of
33 anti-fouling coatings of marine mussel adhesive protein mimics conjugated to 3,4-
34 dihydroxyphenyl-L-alanine-modified poly (ethylene glycol) (mPEG-DOPA(3)) was shown to
35 resist both urinary film formation and uropathogenic attachment *in vitro* when tested with a
36 number of relevant isolates on TiO₂ disks,⁵⁵ although further randomised and large-scale
37 clinical studies are necessary to determine the validity of these coatings.
38
39

40 Zwitterionic Approaches

41 Zwitterionic materials, containing equal positive and negative charge functionalities,
42 maintain electric neutrality and are well-known for their superior antifouling properties.^{56,57}
43 Zwitterionic coatings have recently been applied to polydimethylsiloxane (PDMS), the
44 material most commonly used for the production of silicone Foley catheters.⁵⁸⁻⁶⁰ The
45 incorporation of silver into zwitterionic coatings provides an additional aspect to antifouling
46 coatings of this nature, and has been under recent investigation in several, broad scientific
47 disciplines including membrane processes for water treatment and desalination.⁶¹ The loading
48 of zwitterionic polymer brushes with Ag⁺ precursor ions, followed by their *in situ* reduction
49 to Ag nanoparticles by UV irradiation was investigated by Hu *et al.*⁶² The obtained organic-
50 inorganic hybrid was capable of killing *E.coli* (>99.8% in 1 hour) upon contact with
51 embedded silver nanoparticles, and subsequently releasing dead bacterial cells under wet
52 conditions, preventing the associated immune response and blocking of the antimicrobial
53 function. Similar technology has also been assessed in the terms of wound healing,⁶³ via
54 impregnation of synthesised *in situ* silver nanoparticles into an antifouling zwitterionic
55 hydrogel, thus eliminating the need for additional chemical reductants or toxic solvents. Such
56
57
58
59
60

1
2
3 applications may also be transferrable to the field of urinary catheters, via coating of the outer
4 or inner luminal surfaces with such antimicrobial and antifouling hydrogels.
5

6 Surface Topographical Approaches and Nanostructured Materials

7 The material and resulting surface topography from which a urinary catheter is made can
8 significantly impact the rate of biofilm formation. Latex catheters have a far more uneven
9 surface topography than their silicone counterparts, which promotes microbial adherence,
10 thus accelerating biofilm formation.⁶⁴ Recent studies have aimed to investigate and exploit
11 the abilities of a material's surface topography in order to modulate cellular adhesion.
12 Patterned surfaces, such as Sharklet™ have shown great promise of being a benign surface
13 treatment for the prevention of bacterial attachment.^{65,66} Reddy *et al*⁶⁷ assessed the ability of
14 uropathogenic *E. coli* to colonise three variations of the Sharklet micropattern compared to a
15 standard silicone control. All three variations outperformed controls in the prevention of *E.*
16 *coli* colonisation. An average of 47% reduction in colony-forming units and bacterial area
17 coverage was observed, in addition to 77% reduction in colony size in both tryptic soy broth
18 (TSB) and artificial urine.
19
20

21 Contact Killing and Non-Release-Based Approaches

22
23 Contact killing approaches have gained attention in recent years owing to their ability to
24 circumvent the issue of reservoir exhaustion synonymous with antibacterial agent release
25 coatings. Instead, antimicrobial compounds are covalently anchored to the material surface
26 via polymeric linkers. Bacterial attachment and proliferation is subsequently hindered by
27 such compounds, generally as a result of disruption to the cell membrane via physical lysis or
28 charge disruption.³⁹
29
30

31 Catheter Surface Functionalisation: Plasma Deposition

32 Among methods of antibacterial surface modification of abiotic surfaces, plasma
33 modification plays a rare but increasingly relevant role. With requirements for methods of
34 covalent attachment alternative to solvent-based methods, plasma presents an attractive
35 alternative deposition method which combines ease of preparation and versatility with
36 economical and solvent-free processing. Plasmas, often referred to as the fourth state of
37 matter, are typically generated via the ionisation of a gas by electrical discharge, forming
38 charged particles including ions, electrons and radicals. The species generated exhibit a
39 strong collective response to an applied magnetic field, thus interacting with and modifying
40 surfaces via etching, implantation, deposition or functionalisation.³⁹
41

42 Applications of plasma-treated surfaces per se, to deter bacterial attachment have generally
43 not proved promising, as the arsenal of chemical species available via plasma deposition is
44 limited and does not compete with the complexity of the bacterial attachment process.⁶⁸ A
45 number of studies have used plasma polymerisation to form interlayers for the covalent
46 grafting of antifouling PEG hydrogel layers,^{69,70} including the plasma polymerisation of PEG-
47 like tetra(ethylene glycol) dimethyl ether on to titanium surfaces for reduction of bacterial
48 adhesion to dental implants. The antifouling effect of the coatings was studied by the
49 fluorescent staining of bovine serum albumin (BSA), and showed a reduction in protein
50 adsorption and cell adhesion without any significant cytotoxic effects.⁷¹
51

52 Other approaches of functionalising surfaces to repel/kill bacteria using plasma include
53 deposited composite coatings embedding organic⁷²⁻⁷⁴/inorganic antibacterial agents^{75,76},
54 which have been reviewed in detail elsewhere.⁷⁷ A recent study attempting to address some
55 of the problems of current antibiotic impregnation (including short life-span, narrow
56 spectrum, and antibiotic resistance) has recently described the development of anti-biofilm
57
58
59
60

1
2
3 surfaces using bioactive, membrane-targeting antibacterial peptides.⁷⁸ Peptide-immobilised
4 surfaces were prepared in a two-step process whereby material samples were first activated
5 using argon plasma and then exposed to air to generate hydroperoxide reactive centers.
6 Polymer grafted samples were immersed in lytic peptide solution, resulting in immobilisation
7 via electrostatic interactions between negatively charged polymer chains and positively
8 charged lytic peptides. Evaluation of anti-biofilm surfaces with *S. aureus* showed treated
9 catheters to remain biofilm-free for up to 1 week under conditions of continuous cultivation,
10 as well as increased stability of peptide films upon exposure to **high concentrations of salt**
11 **and biomacromolecules**. Additionally, the low rate of antibiotic resistance and broad
12 antibiotic spectrum makes lytic peptides excellent candidates in the future of CAUTI
13 treatment.
14

15 16 Alternatives to the Foley Catheter

17
18 Despite numerous attempts to develop novel coatings and biomaterials to counteract the
19 complications associated with long-term indwelling catheterisation, the Foley catheter
20 remains the fundamental linchpin in the management of the dysfunctional bladder. Variations
21 of the original catheter design,^{79,80} as well as additive devices⁸¹ to be used with the current
22 clinical set up have been explored in order to circumvent the fundamental design flaws of the
23 Foley catheter. Levering *et al*⁸² have recently designed and optimised a urinary catheter
24 prototype capable of on-demand biofilm removal *in situ*. **Active surface deformation was**
25 **used to detach biofilms from silicone substrates via utilisation of multi-inflation-lumen**
26 **catheters with four intra-wall inflation lumens**, allowing debridement of biofilms from the
27 largely-inaccessible main drainage lumen. This extrudable catheter shaft design was able to
28 supply sufficient strain around the intra-luminal perimeter to cause mixed-species biofilms of
29 *P. mirabilis* and *E. coli* to debond from the material surface (Figure 2). Other attempts to
30 redesign aspects of the urinary catheter away from Foley's original prototype include the
31 trefoil design described by Sun *et al*.⁸³ The trefoil profile of the catheter proved successful in
32 delaying the appearance of culturable organisms when tested in a small *in vivo* trial in rabbits.
33 Variation in catheter design such as the trefoil profile may prove promising in the prevention
34 of CAUTI. As well as the inherent advantages offered by the design itself, catheters such as
35 this may also still be coated with passive or stimuli-responsive release coatings, thus giving
36 the catheter a multifaceted approach to prevention of encrustation and blockage.
37
38

39
40 [Insert Figure 2]

41 42 Infection Detection Systems

43
44 A recently emerging approach to reduce associated patient morbidity and mortality is the
45 detection of the crystalline biofilm formation in advance of catheter blockage. Thus, the
46 catheter may be removed or replaced before the onset of the cascade of associated sequelae.
47 Currently, there is no reliable way of preventing or accurately predicting when blockage may
48 occur.⁸⁴ Patients whose catheters are known to block regularly may be scheduled regular
49 catheter changes, however the unpredictability of catheter blockage remains, often resulting
50 in emergency changes and the associated patient trauma and healthcare costs.⁸⁵

51 **In the case of long-term indwelling urinary catheters, freshly obtained urine from the**
52 **catheterised bladder processed gives 50% more false negatives than urine evaluated in the**
53 **same way from non-catheterised patients.**¹⁴
54
55
56
57
58
59

1
2
3 A simple sensor described by Stickler *et al*⁸⁶ provides a colorimetric signal to warn of
4 impending blockage. The sensor, located within the closed catheter drainage system, employs
5 the dye bromothymol blue (BMB), which displays a pH-dependent colour change over the
6 pH range of 6-8 (yellow to dark blue). Initial testing of cellulose acetate/BMB sensors *in vitro*
7 was capable of giving a clear signal of *P. mirabilis* infection using pH as a proxy indicator.
8 Further development of this system to enable larger scale manufacture employed a silicone-
9 based composite strip design via combination of BMB with polydimethylsiloxanes and a
10 hydrophobic filler.⁸⁷ The resultant strips of sensor material may be housed in a connector and
11 placed within the junction between catheter and drainage bag, where they achieved the same
12 yellow to blue colour change over the desired pH range approximately 19 hours in advance of
13 blockage. Clinical evaluation of this system undertaken by Long *et al*⁸⁸ showed promising
14 results, however the mean time between sensor colour change and catheter blockage was
15 considerably longer in human trials than in the *in vitro* model resulting in an advanced
16 warning of >19 days for the modified design.

17
18 Another dye-based diagnostic system, utilises a dual-layered polymeric system in the form of
19 a catheter coating, whereupon a urinary colour change is resultant from an increase in urinary
20 pH.⁸⁹ The system constitutes a lower hydrogel reservoir layer of poly(vinyl alcohol)
21 containing the self-quenching dye 5(6)-carboxyfluorescein, completely capped and sealed by
22 an upper layer of the pH-responsive polymer poly(methyl methacrylate-*co*-methacrylic acid
23 (EUDRAGITS 100®). Following infection by *P. mirabilis* and subsequent formation of
24 alkaline urine, the outer layer of the coating swells to release the dye in its fluorescent form
25 into the urine, giving a clear visual warning of impending blockage. *In vitro* analysis of the
26 coatings using a clinically relevant artificial bladder demonstrated up to 12 hours advance
27 warning of blockage, exclusively in the presence of urease-positive clinical isolates.

28
29 Surender *et al* have recently described a luminescent lanthanide pH-responsive probe capable
30 of detecting the urease-mediated hydrolysis of urea in aqueous solution.⁹⁰ A series of
31 photophysical titrations showed the Eu(III) chelate behave as an “*on-off*” luminescent
32 switching probe, where the luminescence is quenched upon the conversion of urea to
33 ammonia and carbon dioxide. Impregnation of water-permeable hydrogels with the
34 lanthanide probe showed its potential to be used as a sensor in the field of CAUTI diagnosis
35 (Figure 3A+B). Figure 3C shows the excitation spectra of the swollen Eu-based hydrogel,
36 before and after the addition of urease. The Eu-centered emission was quenched by more than
37 85%, and the resultant colour change from bright red (*on*) to faint pink (*off*) was visible to the
38 naked eye as well as under UV irradiation.

39
40 [Insert Figure 3]

41 42 Part II: Medical Approaches

43 44 Antibiotic-Based Approaches

45
46
47 **Antibiotics have been central to the treatment of bacterial infections (including UTIs) since**
48 **their discovery in 1928.** Most cases of CAUTI are usually categorised as asymptomatic and
49 thus do not require antibiotic prescription.⁷ However, a number of antimicrobials (such as
50 silver alloy and antibiotics) have been approved for use as topical antibacterial impregnated
51 catheters for the prophylaxis of CAUTI.^{7,91,92} These include nitrofurans, nitrofurazone and
52 nitrofurantoin, which are known to have a broad spectrum of activity against Gram-negative
53 and Gram-positive bacteria, and are less prone to causing bacterial resistance.⁹¹ Nevertheless,
54 these commercially available antimicrobial catheters still lack strong evidence to support
55 their routine use in CAUTI management. Clinical trials assessing the performance of silver
56
57
58
59

1
2
3 alloy and nitrofurazone coated catheters in thousands of short-term catheterised patients
4 showed no clinically relevant reduction in CAUTI incidence as compared to untreated
5 catheters.⁹² Furthermore, these catheter-treatments are vulnerable to *P. mirabilis* infections as
6 silver-coated catheters were found to enhance crystalline biofilm formation, while
7 nitrofurazone has little activity against *P. mirabilis* and lacked effective control of catheter
8 blockage.^{93,94} **Full analysis of the efficacy of silver/antibiotic coated/impregnated catheters is
9 beyond the scope of this review, but can be found elsewhere in the literature.**^{95–97}

10 The biocide triclosan has been tested previously for effective prevention of biofilm formation
11 by various uropathogens including *P. mirabilis*, and prevention of catheter blockage.^{98,99} The
12 tests were conducted using representative *in vitro* models of the catheterized urinary tract,
13 simulating a complete closed drainage system as used in clinical practice.¹⁰⁰ Catheter
14 balloons were inflated with triclosan solution (3-10 g/L) diffusing into the bladder lumen in
15 sufficient concentrations to prevent catheter encrustation in models inoculated with *P.*
16 *mirabilis* only⁹⁹ and polymicrobial communities frequently containing *P. mirabilis*.⁹⁸
17 However, it was later revealed that extensive use of triclosan could potentiate an adverse
18 therapeutic effect on *P. mirabilis*. Prolonged exposure of *P. mirabilis* to triclosan on agar
19 plates resulted in selection of *P. mirabilis* mutants with reduced susceptibility to triclosan up
20 to 300-fold, leading to catheter encrustation in models treated with triclosan.¹⁰¹ Such
21 vulnerability of individual antibiotic therapy, can be minimised by combination of antibiotics
22 acting on different targets or using different mechanisms.

23 Fisher *et al.*¹⁰² have reported impregnation of urinary catheters with a combination of
24 rifampicin, sparfloxacin and triclosan (an antibiotic regimen chosen for its broad spectrum
25 against CAUTI pathogens). Using a serial bacterial challenge within an *in vitro* model,
26 antibiotic-impregnated catheter sections were inoculated with bacterial suspensions on a
27 weekly basis, and antimicrobial activity was compared with two commercial silver-processed
28 and nitrofurazone coated catheters. The novel coating demonstrated prevention of *Proteus*
29 *mirabilis*, *Staphylococcus aureus* and *Escherichia coli* colonisation for 7–12 weeks,
30 compared with 1–3 days for the commercially available antimicrobial catheters. **No resistance
31 was detected with any of the test bacterium during the 12 weeks of the flow challenge test.**
32 **However, *P. mirabilis* isolates from catheters from week 8 showed a slight decrease in
33 susceptibility to the antibiotics, suggesting mutational resistance still occurred.** Further
34 studies have demonstrated the efficacy of combined antibiotic formulations to control
35 CAUTIs. For example azithromycin-ciprofloxacin-impregnated catheters were recently
36 shown to avert *P. aeruginosa* bacterial colonization, prevent biofilm formation, and implant-
37 mediated inflammation in a murine model.¹⁰³ Evidence from these studies show that
38 antibiotic therapy is still relevant in CAUTIs. However the rise of antibacterial resistance,
39 where potent antibiotics have been losing their efficacy over time requires alternatives to
40 antibiotics.¹⁰⁴

41 Alternatives to Antibiotics

42 Bacteriophage

43 Bacteriophage (phage) are likely to have high impact as alternatives to antibiotics for the
44 control of CAUTIs. Phage are the natural viral predators of bacteria, and the most abundant
45 biological entity on earth. Existing in nature as non-living particles,¹⁰⁵ they selectively infect
46 bacteria and disrupt normal bacterial metabolism to self-replicate, and kill the bacterial host
47 in the case of lytic phage. Lytic phage, that destroy bacterial cells releasing new phage
48 particles are the most suitable for phage therapy and can be effective at a low phage dose.¹⁰⁶
49 Phage have been investigated for their antibacterial efficacy in a number of scientific
50 disciplines, particularly within therapeutic delivery.¹⁰⁷

1
2
3 Phage have showed great promise in a variety of formats including the development of
4 antibacterial surfaces and biomaterials. In a study by Wang *et al*¹⁰⁸, active lytic bacterial
5 viruses (bacteriophage) were immobilised onto polyhydroxyalkanoate (PHA) surfaces to
6 form an infective antimicrobial surfaces. T4 bacteriophage (phage) immobilised on the
7 surface after treatment with oxygen plasma retained their active conformation and orientation
8 and hence were able to result in clear capture and infection of *E. coli* host cells. No evidence
9 of phage binding was observed on untreated control films. (Figure 4). Such technology is
10 potentially applicable to the treatment of CAUTI, since most polymers undergo similar
11 oxidation during oxygen plasma treatment, thus the technique is widely transferrable to other
12 polymeric substrates.

13 Recent studies have demonstrated the effect of phage against urinary pathogens using *in vitro*
14 models simulating CAUTIs.¹⁰⁹⁻¹¹⁴ Pre-treating hydrogel-coated catheter sections with
15 bacteriophages revealed an approximate 90% reduction in biofilm formation in *E. coli* and *P.*
16 *mirabilis* species,¹⁰⁹ and 99.9% reduction in *P. aeruginosa* biofilms;¹¹⁰ both studies employed
17 a 24-h incubation static *in vitro* model. **Using a two-species biofilm in a continuous-flow *in***
18 ***vitro* model**, Lehman and Donlan¹¹¹ demonstrated the ability of bacteriophage cocktails
19 coated within a hydrogel to reduce *P. aeruginosa* and *P. mirabilis* biofilms on catheters
20 99.9% to 99.8% over 48 hours. Reduction of biofilm formation and prevention of blockage of
21 urinary catheters by *P. mirabilis* were also demonstrated,^{113,114} using representative *in vitro*
22 models of the catheterized urinary tract, simulating a complete closed drainage system as
23 used in clinical practice.¹⁰⁰ When models simulating established infection of 10¹⁰ cells of *P.*
24 *mirabilis*, were treated by a single dose of phage, directly added into the infected bladder
25 model, the therapy significantly increased time taken for catheters to block (~3-fold). Phage
26 therapy was able to completely eradicate early-stage infection consisting of 10³ cells of *P.*
27 *mirabilis*, when challenged with 10¹⁰ phage in bladder models. In these experiments, no
28 viable bacterial cell was recovered from bladder model residual urine, whereas phage
29 particles were still found to be present inside bladder models 8 days after model activation.¹¹³

30
31
32
33 [Insert Figure 4]

34
35 **These studies suggest that high doses of phage delivered at an early stage of infection could**
36 **lead to effective phage therapy**, which is often hampered by development of phage-resistance
37 reported in models with established infections.^{111,113} Development of bacterial resistance to
38 phage infection is usually caused by spontaneous mutations in host cell populations over
39 time, or bacterial adaptation in response to selective pressure exerted by the bacteriophage.¹¹⁵
40 This leads to modifications in phage receptors, affecting phage-host interactions and
41 efficiency of infection. One way to overcome phage resistance is the use of phage cocktails,
42 where multiple phage are used in mixed dose therapy, resulting in broader antibacterial
43 spectrum of activity.^{116,117} Despite the great promise that phage therapy has shown
44 throughout a number of scientific disciplines in recent years, the regulatory barriers are
45 considerable and must be overcome before this can truly be seen as a viable treatment
46 option.¹⁰⁷

47 48 49 **Drugs with Efflux Pump Activities**

50 Efflux pump systems are transport proteins that bacteria use to extrude toxic agents, including
51 antibiotics.¹¹⁸ In their study investigating the genetic basis of biofilm formation in *P.*
52 *mirabilis*, Holling *et al.*¹¹⁹ demonstrated that efflux systems are essential in the formation
53 of *P. mirabilis* crystalline biofilms. This was revealed by phenotypic characterisation of *P.*
54 *mirabilis* mutants, which showed reduced ability to form crystalline biofilms and block
55 catheters compared to the wild-type strain. Genetically, these mutants were disrupted in
56
57
58
59
60

1
2
3 the *Bcr/CflA* (a subfamily of efflux system).¹¹⁹ This discovery led to further investigations for
4 the potential for efflux pump inhibitors (EPIs) to control bacterial biofilm formation and
5 catheter blockage by *P. mirabilis*. By screening several drugs already commonly used in
6 human medicine, with potential EPI activity in other bacterial species,^{120,121} Nzakizwanayo *et*
7 *al.*¹²² demonstrated the effect of fluoxetine and thioridazine to act as EPIs in *P. mirabilis*, and
8 control biofilm formation and blockage of catheters. Fluoxetine is a selective serotonin re-
9 uptake inhibitor (SSRI), marketed as Prozac, and thioridazine is an antipsychotic-drug. This
10 study shows that repurposing of existing drugs with EPI activity as a novel approach to
11 control catheter blockage.
12

13 Quorum-Sensing Inhibitors

14 The quorum-sensing (QS) system is a regulatory mechanism by which bacterial cells
15 communicate via a chemical vocabulary (e.g. N-acyl homoserine lactones (AHLs) in Gram
16 negative bacteria). Concentration of AHLs increases as the bacterial population grows, and
17 upon reaching a threshold, binding to receptor molecules occurs. This binding acts as a
18 transcriptional regulator on genes of the QS system and contributes to the production of
19 virulence factors that aid biofilm formation.¹²³ Molecules and enzymes targeting this bacterial
20 communication system have recently been investigated in the field of CAUTI as novel anti-
21 biofilm agents. Jones *et al.*¹²⁴ investigated two QS antagonists, tannic acid and *p*-nitrophenyl
22 glycerol, finding that both were capable of controlling the crystalline biofilms of *P. mirabilis*.
23 Anti-biofilm and anti-quorum sensing compounds from secondary metabolites of halophiles
24 marine *Streptomyces* have recently been assessed by Younis *et al.*¹²⁵ Isolate sediment lake
25 Iraq (sdLi) showed promising inhibition of *P. mirabilis* biofilm formation on urinary catheter,
26 as well as attenuation of QS-dependent factors such as hemolysin activity, urease activity, pH
27 and bacterial motility.
28

29 Coatings utilising the immobilisation of the enzyme acylase (from *Aspergillus melleus*) on
30 biomedical grade polyurethane coatings via multipoint covalent immobilisation have shown
31 to have potential in biofilm prevention via quorum sensing-disruption.¹²⁶ Coatings containing
32 amylase were shown to enzymatically catalyse the hydrolysis of the quorum sensing
33 molecules *s* N-butyryl-L-homoserine lactone (C4-LHL), N-hexanoyl-L-homoserine lactone
34 (C6-LHL), and N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-LHL), and showed
35 an approximately 60% reduction in biofilm formation by two clinical isolates of *P.*
36 *aeruginosa*. A similar approach investigated by Ivanova *et al.*¹²⁷ where multi-layered
37 coatings of acylase and α -amylase (able to degrade quorum sensing autoinducers and
38 polysaccharides, respectively), deposited on urinary catheters via layer-by-layer techniques
39 displayed quorum quenching and matrix-degrading abilities, delaying biofilm growth of
40 relevant uropathogens by up to 7 days *in vivo*.
41

42 Enzymes

43 The preparation and antibacterial properties of an enzyme-embedded polycaprolactone
44 (PCL)-based coating have been investigated by Dave *et al.*¹²⁸ The coating, impregnated with
45 the antibiotic compound gentamicin sulphate (GS), utilises PCL itself as a substrate for the
46 enzyme lipase, resulting in release of GS at a rate controlled by degradation of the PCL base.
47 Modulation of enzyme concentration in PCL films allowed control of GS release from the
48 coating from 16 to 33 days, also resulting in complete degradation of the polymer film so that
49 no residual polymer substratum could serve as a base for possible microbial adherence post
50 antibiotic release. The polymer showed antibacterial effects against three test isolates: *E. coli*,
51 *S. aureus*, and *P. aeruginosa*, and displayed sustained release *in vitro* over a period of 60
52 hours when coated onto urinary catheters. The results suggest that the tunable, self-degrading
53 coatings prove a promising candidate for use in urinary catheters, although enzyme
54 biocompatibility within the bladder could prove problematic.
55
56
57
58
59
60

Enzymes have also been incorporated into catheter lubricants in order to investigate their potential in the field of CAUTI. Thallinger *et al*¹²⁹ examined the ability of cellobiose dehydrogenase (CDH) to produce hydrogen peroxide for antibiotic and antibiofilm functionalisation of urinary catheters. Biofilm formation of silicone films was prevented by 1 mM CDH (recombinantly produced from *Myriococcus thermophilum*), and the growth of many common uropathogens, including *P. mirabilis*, was inhibited. The aforementioned antibiofilm activities were found to be strongly enhanced when used in the presence of α -linked glycosides, as the consequent hydrolysis of polysaccharides increases the number of terminal reducing sugars as substrates for CDH as well as causing destabilisation of the biofilm.

Part III: Stimuli-Responsive Approaches

Alongside the current engineering and passive release strategies aimed at preventing catheter blockage, additional research has focused on stimuli-responsive systems. Such systems rely on an external stimulus (either directly or indirectly associated with the onset of infection) in order to facilitate diagnosis or treatment. Direct indicators of infection include specific biomarkers produced by pathogenic bacteria (such as enzymes or toxins), whilst a change in the local environment may indirectly confirm infection via bacterial or immune activity (e.g. a change in pH or temperature). Stimuli-responsive materials retain their diagnostic or therapeutic potential until an endogenous factor initiates a burst response of the cargo contained within. This may manifest as a change in volume or structure of the material (in the case of polymeric or hydrogel formulations), or as a result of bond cleavage of anchored moieties.³⁹ The ability to control both the release kinetics and the delivery location of a diagnostic or therapeutic agent offers certain advantages over conventional passive release systems including: protection of the often sensitive cargo from harsh external conditions and avoidance of any unnecessary or sub-lethal exposure, thus limiting any subsequent evolution of bacterial resistance. The controlled release concept is especially attractive in the treatment of CAUTI owing to the time-dependent delivery of the therapeutic cargo. In addition to the aforementioned precautions, premature administration of a therapeutic agent to the bladder will inevitably result in timely elution, rendering the system ineffective in successfully clearing a progressive infection.

The urease-catalysed conversion of urea into ammonia by certain urinary pathogens (in particular *P. mirabilis*), and the resultant increase in urine pH has been exploited in the development of a number of pH-responsive catheter coatings. The pH-responsive polymer Eudragit S100® (poly (methylmethacrylate-co-methacrylic acid)) has been developed in order to deliver bacteriophage from coated catheters in order to delay blockage. Prior to any elevation in urine pH, *P. mirabilis* bacteriophage contained within the PVA reservoir layer are unable to elicit any bactericidal effects. However, upon an infection-associated increase in urine pH and the subsequent dissolution of the Eudragit layer, the phage are able to diffuse into the bladder, reducing bacterial load by up to 6-log within 2 hours. Overall, this resulted in doubling the time to blockage (26 hours compared to 13 hours for the uncoated catheters), ultimately extending the catheter lifetime by 100%.¹¹⁴

An alternative strategy in the development of pH-responsive catheter coatings utilises the solubility of specific drug formulations in order to modulate their release from polymeric hydrogels. Nalidixic acid (a pH sensitive antimicrobial quinolone) has been successfully loaded into polymeric films of poly(2-Hydroxyethylmethacrylate) co-polymerised with methyl methacrylate. Owing to the presence of an ionisable carboxyl group within the quinolone structure, the mechanism of pH-dependent drug release relies on the affinity of the

1
2
3 ionised drug (at alkaline pH) towards aqueous media (urine), resulting in diffusion out of the
4 carrier matrix and into the surrounding area. **As opposed to conventional polymeric triggered**
5 **release systems**, this formulation does not rely on a structural change in the polymeric carrier
6 in order to facilitate antimicrobial expulsion, rather the chemical properties of the
7 antimicrobial itself govern the rate of drug release. Utilising a hydrophobic polymer, the
8 release kinetics of the drug were controlled in order to provide sustained zero-order drug
9 diffusion over the course of weeks, as oppose to hours as reported with more hydrophilic
10 polymers.¹³⁰ Moreover, a series of polymerisable ester naphthyridinone conjugates have been
11 synthesised with varying chain lengths. The base-catalysed hydrolysis of the ester bond
12 linking the nalidixic acid to the vinyl spacer arm determines the rate of pH-dependent drug
13 release when anchored to polymeric biomaterials.¹³¹ Further studies have developed this
14 concept using the aforementioned vinyl-functionalised nalidixic acid and crosslinked 2-
15 hydroxyethyl methacrylate hydrogels, forming antimicrobial pro-drug matrices. *In-vitro*
16 results exhibited negligible drug release at physiological pH, while the triggered, prolonged
17 release of nalidixic acid was up to 20-fold faster and approximated 80% after 6 weeks at pH
18 10.¹³²

19
20 In contrast to utilising a change in the external environment, specific bacterial biomarkers
21 have been exploited in order to induce the release of antibacterial agents via disassembly of
22 polycationic nanospheres. Aminocellulose (AC), an effective antimicrobial agent owing to its
23 propensity towards bacterial membrane disruption, has been formulated into nanospheres and
24 incorporated into a multi-layer coating capable of preventing *P. aeruginosa* biofilm
25 formation. The formulation comprises AC nanospheres coated with hyaluronic acid, the outer
26 layer is degraded by pyocyanin (a redox active virulence factor produced by *P. aeruginosa*)
27 thus liberating the antimicrobial components within. Planktonic bacterial growth was reduced
28 by 70% after 2 hours ($p < 0.001$), whereas under dynamic conditions (bladder model
29 experiments) effective catheter biofilm prevention was confirmed via fluorescence
30 microscopy as shown in Figure 5.¹³³

31
32
33 [Insert Figure 5]

34 35 36 Concluding Remarks and Future Perspective

37
38 Whilst it is widely acknowledged that the clinical, social and economic burden associated
39 with the use of the Foley catheter for long-term indwelling catheterisation has gained
40 notoriety in recent years, it is also true to say that regulatory authorities, relevant industrial
41 and commercial companies as well as the scientific community has thus far failed to seek a
42 comprehensive solution. This is likely owing to the fact that in order to achieve such an
43 extensive and complex scientific undertaking, the nature of the necessary research is
44 inherently multidisciplinary. The marriage of broad and often tenuously linked scientific
45 disciplines must occur in order to truly overcome the problem of encrustation and blockage of
46 Foley catheters. Indeed, it is the responsibility of the commercial companies and regulatory
47 authorities to positively encourage innovation for an application where existing devices are so
48 clearly inadequate. Taking into account the research presented in this review, future attempts
49 to improve the urinary catheter system must involve the marriage of chemical, biological and
50 engineering advancements, whilst still maintaining the assets of the original design. It is
51 necessary for research funders, healthcare services and governing bodies to stimulate
52 interdisciplinary research amongst the scientific, engineering, industrial and clinical
53 communities to meet and overcome the challenge.

Moreover, passive release of antimicrobial cargos should not be considered a panacea or universally effective strategy as previously regarded. Rather, they should be considered part of a concerted effort to control known risk factors of CAUTI, and the basis of more advanced and microbiologically fool proof methods, such as stimuli-responsive release. Such 'smart' coatings provide the basis of a multifaceted solution in which the properties and local concentration of the antimicrobial agent are maintained whilst limiting systemic exposure, thus taking into consideration the challenge of introducing such species into the catheterised bladder. Despite recent advances in this field, several key challenges must be overcome in order for triggered release coatings to become a truly valued tool in the CAUTI-preventative arsenal, including long term stability, maintenance of catheter functionality and ease of commercial manufacture.

In conclusion, the review has identified the current advances within the fields of medicine and biomedical engineering, which must now be used in combination in order to maximise their efficacy and broaden their field of application. Despite the large amount of reported approaches throughout the literature, few platforms have progressed to clinical studies, and even fewer to clinical practice. The lack of translational success can be attributed in part to the inherent complexity of the problem and the necessity of the multidisciplinary approach necessary to overcome it. Objective evaluations of coating stability, specific to the challenge of CAUTI have often been similarly overlooked. Specifically structured research is therefore paramount to develop validation methods for technologies such as stimuli responsive coatings, such that clinical efficacy may be effectively extrapolated. Overcoming these challenges will require collaborative effort from those working across a wide variety of disciplines (in particular the field of biomedical science), but success will offer ample opportunity for innovation, as well as a long-overdue solution to a complex clinical problem.

Declaration of Conflicting Interests

The authors received no financial support for the research, authorship and/or publication of this article.

References

1. Saint S, Wiese J, Amory JK, et al. Are physicians aware of which of their patients have indwelling urinary catheters? *American Journal of Medicine* 2000; 109: 476–480.
2. Feneley RCL, Hopley IB, Wells PNT. Urinary catheters: history, current status, adverse events and research agenda. *Journal of medical engineering & technology* 2015; 39: 459–470.
3. Delcaru C, Alexandru I, Podgoreanu P, et al. Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating Strategies. *Pathogens* 2016; 65: 1–12.
4. Armbruster C, Mobley H. Merging Mythology and Morphology: the multifaceted lifestyle of *Proteus mirabilis*. *Nature Reviews Microbiology* 2012; 10: 743–754.
5. Feneley RCL, Hopley IB, Wells PNT. Urinary catheters: history, current status, adverse events and research agenda. *Journal of medical engineering & technology* 2015; 39: 459–70.
6. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. *Science* 2004; 303: 1522–1526.
7. Jacobsen SM, Stickler DJ, Mobley HLT, et al. Complicated catheter-associated urinary

- tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clinical Microbiology Reviews* 2008; 21: 26–59.
8. Leranoz S, Orús P, Berlanga M, et al. New fimbrial adhesins of *Serratia marcescens* isolated from urinary tract infections: Description and properties. *Journal of Urology* 1997; 157: 694–698.
 9. Daifuku R, Stamm WE. Bacterial adherence to bladder uroepithelial cells in catheter-associated urinary tract infection. *New England Journal of Medicine* 1986; 314: 208–213.
 10. Warren JW. Clinical presentations and epidemiology of urinary tract infections. In: *Urinary tract infections: molecular pathogenesis and clinical management*. Washington DC: ASM Press, 1996, pp. 28–32.
 11. Tambyah PA, Halvorson KT, Maki DG. A prospective study of pathogenesis of catheter-associated urinary tract infections. *Mayo Clinic proceedings* 1999; 74: 131–6.
 12. Warren JW. Catheter-associated urinary tract infections. *International journal of antimicrobial agents* 2001; 17: 299–303.
 13. Siddiq DM, Darouiche RO. New strategies to prevent catheter-associated urinary tract infections. *Nature Reviews Urology* 2012; 9: 305–314.
 14. Høiby N, Bjarnsholt T, Moser C, et al. ESCMID* guideline for the diagnosis and treatment of biofilm infections 2014. *Clinical Microbiology and Infection* 2015; 21: S1–S25.
 15. European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance surveillance in Europe 2014. *European Centre for Disease Prevention and Control*.
 16. Nicolle LE. Catheter associated urinary tract infections. 2014; 3: 1–8.
 17. Elves AWS, Feneley RCL. Long-term urethral catheterization and the urine-biomaterial interface. *British Journal of Urology* 1997; 80: 1–5.
 18. Denstedt J, Wollin TA, Reid G. Biomaterials Used in Urology: Current Issues of Biocompatibility, Infection, and Encrustation. *Journal of Endourology* 2009; 12: 493–500.
 19. Lewis A. *Drug Device Combination Products: Delivery Technologies and Applications*. 1st ed. Oxford, UK: Woodhead Publishing Ltd, 2010.
 20. Carr H. A short history of the Foley catheter: from handmade instrument to infection-prevention device. *Journal of Endourology* 2000; 14: 5–8.
 21. Foley FEB. A Hemostatic Bag Catheter. *The Journal of Urology* 1937; 38: 134–139.
 22. Morris NS, Stickler DJ, McLean RJ. The development of bacterial biofilms on indwelling urethral catheters. *World journal of urology* 1999; 17: 345–50.
 23. Wang R, Neoh KG, Kang E-T, et al. Antifouling coating with controllable and sustained silver release for long-term inhibition of infection and encrustation in urinary catheters. *Journal of Biomedical Materials Research - Part B: Applied Biomaterials* 2015; 103: 519–528.
 24. Sabbuba N, Hughes G, Stickler DJ. The migration of *Proteus mirabilis* and other urinary tract pathogens over Foley catheters. *BJU International* 2002; 89: 55–60.
 25. Roberts JA, Everett N, Fussell M, et al. Bacterial Adherence to Urethral Catheters. *The Journal of Urology* 1990; 144: 264–269.
 26. Broomfield RJ, Morgan SD, Khan A, et al. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: A simple method of control. *Journal of Medical Microbiology* 2009; 58: 1367–1375.
 27. Anghel I, Grumezescu AM, Holban AM, et al. Biohybrid nanostructured iron oxide nanoparticles and *Satureja hortensis* to prevent fungal biofilm development. *International Journal of Molecular Sciences* 2013; 14: 18110–18123.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
28. Macleod SM, Stickler DJ. Species interactions in mixed-community crystalline biofilms on urinary catheters. *Journal of Medical Microbiology* 2007; 56: 1549–1557.
29. O’Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of *Proteus*, *Providencia*, and *Morganella*. *Clinical Microbiology Reviews* 2000; 13: 534–546.
30. Armbruster CE, Mobley HLT. Merging mythology and morphology: the multifaceted lifestyle of *Proteus mirabilis*. *Nature Reviews Microbiology* 2012; 10: 743–754.
31. Anjum S, Singh S, Benedicte L, et al. Biomodification Strategies for the Development of Antimicrobial Urinary Catheters: Overview and Advances. *Global Challenges* 2018; 2: 1–14.
32. Poore CA, Mobley HLT. Differential regulation of the *Proteus mirabilis* urease gene cluster by *UreR* and *H-NS*. *Microbiology* 2003; 149: 3383–3394.
33. Zambelli B, Musiani F, Benini S, et al. Chemistry of Ni^{2+} in urease: Sensing, trafficking, and catalysis. *Accounts of Chemical Research* 2011; 44: 520–530.
34. Stickler DJ, Lear JC, Morris NS, et al. Observations on the adherence of *Proteus mirabilis* onto polymer surfaces. *Journal of applied microbiology* 2006; 100: 1028–33.
35. Jacobsen SM, Stickler DJ, Mobley HLT, et al. Complicated Catheter-Associated Urinary Tract Infections Due to *Escherichia coli* and *Proteus mirabilis*. *Clinical Microbiology Reviews* 2008; 21: 26–59.
36. Cestari SE, Ludovico MS, Martins FH, et al. Molecular detection of *HpmA* and *HlyA* hemolysin of uropathogenic *proteus mirabilis*. *Current Microbiology* 2013; 67: 703–707.
37. Alamuri P, Mobley HLT. A novel autotransporter of uropathogenic *Proteus mirabilis* is both a cytotoxin and an agglutinin. *Molecular Microbiology* 2008; 68: 997–1017.
38. Holowka EP, Bhatia SK. Controlled-Release Systems. In: *Drug Delivery*. New York, NY: Springer, 2014, pp. 7–62.
39. Cloutier M, Mantovani D, Rosei F. Antibacterial Coatings: Challenges, Perspectives, and Opportunities. *Trends in Biotechnology* 2015; 33: 637–652.
40. Campoccia D, Montanaro L, Arciola CR. A review of the biomaterials technologies for infection-resistant surfaces. *Biomaterials* 2013; 34: 8533–8554.
41. Shalom Y, Perelshtein I, Perkas N, et al. Catheters coated with Zn-doped CuO nanoparticles delay the onset of catheter-associated urinary tract infections. *Nano Research* 2017; 10: 520–533.
42. Margel D, Mizrahi M, Regev-Shoshani G, et al. Nitric oxide charged catheters as a potential strategy for prevention of hospital acquired infections. *PLoS ONE*; 12. Epub ahead of print 2017. DOI: 10.1371/journal.pone.0174443.
43. Singha P, Pant J, Goudie MJ, et al. Enhanced antibacterial efficacy of nitric oxide releasing thermoplastic polyurethanes with antifouling hydrophilic topcoats. *Biomater Sci* 2017; 5: 1246–1255.
44. Kishikawa H, Ebberyd A, Römling U, et al. Control of pathogen growth and biofilm formation using a urinary catheter that releases antimicrobial nitrogen oxides. *Free Radical Biology and Medicine* 2013; 65: 1257–1264.
45. Colletta A, Wu J, Wo Y, et al. S-Nitroso-N-acetylpenicillamine (SNAP) Impregnated Silicone Foley Catheters: A Potential Biomaterial/ Device To Prevent CatheterAssociated Urinary Tract Infections. *ACS Biomaterials Science & Engineering* 2015; 1: 416–424.
46. Beiko DT, Knudsen BE, Watterson JD, et al. Urinary tract biomaterials. *Journal of Urology* 2004; 171: 2438–2444.
47. McCoy CP, Irwin NJ, Donnelly L, et al. Anti-Adherent Biomaterials for Prevention of Catheter Biofouling. *International Journal of Pharmaceutics* 2018; 535: 420–427.


- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
48. Kazmierska KA, Thompson R, Morris N, et al. In vitro multicompartmental bladder model for assessing blockage of urinary catheters: Effect of hydrogel coating on dynamics of proteus mirabilis growth. *Urology*; 76. Epub ahead of print 2010. DOI: 10.1016/j.urology.2010.04.039.
49. Larraneta E, Henry M, Irwin NJ, et al. Synthesis and characterisation of hyaluronic acid hydrogels crosslinked using a solvent-free process for potential biomedical applications. *Carbohydrate Polymers* 2018; 181: 1194–1205.
50. Dunne WM. Bacterial adhesion: seen any good biofilms lately? *Clinical Microbiology Reviews* 2002; 15: 155–166.
51. Lowe S, O'Brien-Simpson NM, Connal LA. Antibiofouling polymer interfaces: poly(ethylene glycol) and other promising candidates. *Polym Chem* 2015; 6: 198–212.
52. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. *Angewandte Chemie - International Edition* 2010; 49: 6288–6308.
53. Konradi R, Acikgoz C, Textor M. Polyoxazolines for Nonfouling Surface Coatings — A Direct Comparison to the Gold Standard PEG. *Macromolecular Rapid Communications* 2012; 33: 1663–1676.
54. Lau KHA, Ren C, Park SH, et al. An experimental-theoretical analysis of protein adsorption on peptidomimetic polymer brushes. *Langmuir* 2012; 28: 2288–2298.
55. Ko R, Cadieux PA, Dalsin JL, et al. Novel Uropathogen-Resistant Coatings Inspired by Marine Mussels. *Journal of Endourology* 2008; 22: 1153–1160.
56. Chen S, Li L, Zhao C, et al. Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials. *Polymer* 2010; 51: 5283–5293.
57. Jeon SI, Lee JH, Andrade JD, et al. Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory. *Journal of Colloid And Interface Science* 1991; 142: 149–158.
58. Dundua A, Franzka S, Ulbricht M. Improved Antifouling Properties of Polydimethylsiloxane Films via Formation of Polysiloxane/Polyzwitterion Interpenetrating Networks. *Macromolecular Rapid Communications* 2016; 37: 2030–2036.
59. Vaterrodt A, Thallinger B, Daumann K, et al. Antifouling and Antibacterial Multifunctional Polyzwitterion/Enzyme Coating on Silicone Catheter Material Prepared by Electrostatic Layer-by-Layer Assembly. *Langmuir* 2016; 32: 1347–1359.
60. Yeh SB, Chen CS, Chen WY, et al. Modification of silicone elastomer with zwitterionic silane for durable antifouling properties. *Langmuir* 2014; 30: 11386–11393.
61. Zhang DY, Hao Q, Liu J, et al. Antifouling polyimide membrane with grafted silver nanoparticles and zwitterion. *Separation and Purification Technology* 2018; 192: 230–239.
62. Hu R, Li G, Jiang Y, et al. Silver-zwitterion organic-inorganic nanocomposite with antimicrobial and antiadhesive capabilities. *Langmuir* 2013; 29: 3773–3779.
63. Ghavaminejad A, Park CH, Kim CS. In Situ Synthesis of Antimicrobial Silver Nanoparticles within Antifouling Zwitterionic Hydrogels by Catecholic Redox Chemistry for Wound Healing Application. *Biomacromolecules* 2016; 17: 1213–1223.
64. Stickler D, Young R, Jones G, et al. Why are Foley catheters so vulnerable to encrustation and blockage by crystalline bacterial biofilm? *Urological Research* 2003; 31: 306–311.
65. May RM, Magin CM, Mann EE, et al. An engineered micropattern to reduce bacterial colonization, platelet adhesion and fibrin sheath formation for improved biocompatibility of central venous catheters. *Clinical and Translational Medicine*

- 2015; 4: 9.
66. Vasudevan R, Kennedy AJ, Merritt M, et al. Microscale patterned surfaces reduce bacterial fouling-microscopic and theoretical analysis. *Colloids and Surfaces B: Biointerfaces* 2014; 117: 225–232.
67. Reddy ST, Chung KK, McDaniel CJ, et al. Micropatterned Surfaces for Reducing the Risk of Catheter-Associated Urinary Tract Infection: An In Vitro Study on the Effect of Sharklet Micropatterned Surfaces to Inhibit Bacterial Colonization and Migration of Uropathogenic *Escherichia coli*. *Journal of Endourology* 2011; 25: 1547–1552.
68. Vasilev K, Griesser SS, Griesser HJ. Antibacterial surfaces and coatings produced by plasma techniques. *Plasma Processes and Polymers* 2011; 8: 1010–1023.
69. Hamilton-Brown P, Gengenbach T, Griesser HJ, et al. End terminal, poly(ethylene oxide) graft layers: surface forces and protein adsorption. *Langmuir* 2009; 25: 9149–9156.
70. Chang Y, Cheng TY, Shih YJ, et al. Biofouling-resistance expanded poly(tetrafluoroethylene) membrane with a hydrogel-like layer of surface-immobilized poly(ethylene glycol) methacrylate for human plasma protein repulsions. *Journal of Membrane Science* 2008; 323: 77–84.
71. Buxadera-Palomero J, Canal C, Torrent-Camarero S, et al. Antifouling coatings for dental implants: Polyethylene glycol-like coatings on titanium by plasma polymerization. *Biointerphases* 2015; 10: 29505.
72. Da Ponte G, Sardella E, Fanelli F, et al. Atmospheric pressure plasma deposition of poly lactic acid-like coatings with embedded elastin. *Plasma Processes and Polymers* 2014; 11: 345–352.
73. Heyse P, Roeffaers MBJ, Paulussen S, et al. Protein immobilization using atmospheric-pressure dielectric-barrier discharges: A route to a straightforward manufacture of bioactive films. *Plasma Processes and Polymers* 2008; 5: 186–191.
74. Heyse P, Van Hoeck A, Roeffaers MBJ, et al. Exploration of atmospheric pressure plasma nanofilm technology for straightforward bio-active coating deposition: Enzymes, plasmas and polymers, an elegant synergy. *Plasma Processes and Polymers* 2011; 8: 965–974.
75. Kumar V, Jolivalt C, Pulpytel J, et al. Development of silver nanoparticle loaded antibacterial polymer mesh using plasma polymerization process. *Journal of Biomedical Materials Research - Part A* 2013; 101 A: 1121–1132.
76. Deng X, Yu Nikiforov A, Coenye T, et al. Antimicrobial nano-silver non-woven polyethylene terephthalate fabric via an atmospheric pressure plasma deposition process. *Scientific Reports*; 5. Epub ahead of print 2015. DOI: 10.1038/srep10138.
77. Sardella E, Palumbo F, Camporeale G, et al. Non-equilibrium plasma processing for the preparation of antibacterial surfaces. *Materials*; 9. Epub ahead of print 2016. DOI: 10.3390/ma9070515.
78. Traba C, Liang JF. Bacteria responsive antibacterial surfaces for indwelling device infections. *Journal of Controlled Release* 2015; 198: 18–25.
79. Flinchbaugh DE. *Conformable Balloonless Catheter*. US6855126B2, US, 2005.
80. Britt RG. *Urinary catheter that prevents bladder infections*. US20130030415A1, US, 2011.
81. Zumeris J, Jacob H. *Acoustic Add-On Device for Biofilm Prevention in Urinary Catheter*. US7829029B2, US, 2010.
82. Levering V, Cao C, Shivapooja P, et al. Urinary catheter capable of repeated on-demand removal of infectious biofilms via active deformation. *Biomaterials* 2016; 77: 77–86.
83. Sun Y, Zeng Q, Zhang Z, et al. Decreased urethral mucosal damage and delayed

- 1
2
3 bacterial colonization during short-term urethral catheterization using a novel trefoil
4 urethral catheter profile in rabbits. *Journal of Urology* 2011; 186: 1497–1501.
- 5 84. Gould C, Umscheid CA, Agarwal RK, et al. Guideline for prevention of catheter-
6 associated urinary tract infections. *Infection Control & Hospital Epidemiology* 2010;
7 31: 319–326.
- 8 85. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of
9 catheter-associated urinary tract infection in adults: 2009 International Clinical
10 Practice Guidelines from the Infectious Diseases Society of America. *Clinical
11 infectious diseases : an official publication of the Infectious Diseases Society of
12 America* 2010; 50: 625–63.
- 13 86. Stickler DJ, Jones SM, Adusei GO, et al. A Sensor to Detect the Early Stages in
14 Development of Crystalline *Proteus mirabilis* Biofilm on Indwelling Bladder
15 Catheters. *Journal of Clinical Microbiology* 2006; 44: 1540–1542.
- 16 87. Malic S, Waters MG, Basil L, et al. Development of an ‘early warning’ sensor for
17 encrustation of urinary catheters following *Proteus* infection. *Journal of Biomedical
18 Materials Research* 2012; 100B: 133–137.
- 19 88. Long A, Edwards J, Thompson R, et al. A clinical evaluation of a sensor to detect
20 blockage due to crystalline biofilm formation on indwelling urinary catheters. *BJU
21 International* 2014; 114: 278–285.
- 22 89. Milo S, Thet NT, Liu D, et al. An in-situ infection detection sensor coating for urinary
23 catheters. *Biosensors and Bioelectronics* 2016; 81: 166–172.
- 24 90. Surender EM, Bradberry SJ, Bright SA, et al. Luminescent lanthanide cyclen-based
25 enzymatic assay capable of diagnosing the onset of catheter-associated urinary tract
26 infections both in solution and within polymeric hydrogels. *Journal of the American
27 Chemical Society* 2017; 139: 381–388.
- 28 91. Guay DR. An update on the role of nitrofurans in the management of urinary tract
29 infections. *Drugs* 2001; 61: 353–364.
- 30 92. Pickard R, Lam T, Maclennan G, et al. Antimicrobial catheters for reduction of
31 symptomatic urinary tract infection in adults requiring short-term catheterisation in
32 hospital: a multicentre randomised controlled trial. *Lancet* 2012; 380: 1927–1935.
- 33 93. Stickler DJ, Morgan SD. Observations on the development of the crystalline bacterial
34 biofilms that encrust and block Foley catheters. *Journal of Hospital Infection* 2008; 69:
35 350–360.
- 36 94. Stickler DJ. Clinical complications of urinary catheters caused by crystalline biofilms:
37 Something needs to be done. *Journal of Internal Medicine* 2014; 276: 120–129.
- 38 95. Politano AD, Campbell KT, Rosenberger LH, et al. Use of Silver in the Prevention and
39 Treatment of Infections: Silver Review. *Surgical Infections* 2013; 14: 8–20.
- 40 96. Pickard R, Lam T, Maclennan G, et al. Antimicrobial catheters for reduction of
41 symptomatic urinary tract infection in adults requiring short-term catheterisation in
42 hospital : a multicentre randomised controlled trial. *The Lancet* 2012; 380: 1927–1935.
- 43 97. Singha P, Locklin J, Handa H. A review of the recent advances in antimicrobial
44 coatings for urinary catheters. *Acta Biomaterialia* 2017; 50: 20–40.
- 45 98. Williams GJ, Stickler DJ. Effect of triclosan on the formation of crystalline biofilms
46 by mixed communities of urinary tract pathogens on urinary catheters. *Journal of
47 Medical Microbiology* 2008; 57: 1135–1140.
- 48 99. Jones GL, Muller CT, O’Reilly M, et al. Effect of triclosan on the development of
49 bacterial biofilms by urinary tract pathogens on urinary catheters. *The Journal of
50 antimicrobial chemotherapy* 2006; 57: 266–72.
- 51 100. Stickler D, Morris N, Winters C. Simple Physical Model to Study Formation and
52 Physiology of Biofilms on Urethral Catheters. *Methods in Enzymology* 1999; 310:
53
54
55
56
57
58
59
60

- 1
2
3 498–501.
- 4 101. Stickler DJ, Jones GL. Reduced susceptibility of *Proteus mirabilis* to triclosan.
5 *Antimicrobial Agents and Chemotherapy* 2008; 52: 991–994.
- 6 102. Fisher LE, Hook AL, Ashraf W, et al. Biomaterial modification of urinary catheters
7 with antimicrobials to give long-term broadspectrum antibiotic activity. *Journal of*
8 *Controlled Release* 2015; 202: 57–64.
- 9 103. Saini H, Vadekeetil A, Chhibber S, et al. Azithromycin-ciprofloxacin-impregnated
10 urinary catheters avert bacterial colonization, biofilm formation, and inflammation in a
11 murine model of foreign-body-associated urinary tract infections caused by
12 *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*; 61. Epub ahead of
13 print 2017. DOI: 10.1128/AAC.01906-16.
- 14 104. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio
15 review. *The Lancet Infectious Diseases* 2016; 16: 239–251.
- 16 105. Hendrix RW. Bacteriophages: Evolution of the Majority. *Theoretical Population*
17 *Biology* 2002; 61: 471–480.
- 18 106. Sulakvelidze A, Alavidze Z. Bacteriophage Therapy. *Antimicrobial Agents and*
19 *Chemotherapy* 2001; 45: 649–659.
- 20 107. Hathaway H, Milo S, Sutton JM, et al. Recent advances in therapeutic delivery
21 systems of bacteriophage and bacteriophage-encoded endolysins. *Therapeutic Delivery*
22 2017; 8: 543–556.
- 23 108. Wang C, Sauvageau D, Elias A. Immobilization of Active Bacteriophages on
24 Polyhydroxyalkanoate Surfaces. *ACS Applied Materials and Interfaces* 2016; 8: 1128–
25 1138.
- 26 109. Carson L, Gorman SP, Gilmore BF. The use of Lytic Bacteriophages in the Prevention
27 and Eradication of Biofilms of *Proteus mirabilis* and *Escherichia coli*. *FEMS*
28 *Immunology and Medical Microbiology* 2010; 59: 447–455.
- 29 110. Fu W, Forster T, Mayer O, et al. Bacteriophage Cocktail for the Prevention of Biofilm
30 Formation by *Pseudomonas aeruginosa* on Catheters in an In Vitro Model System.
31 *Antimicrobial Agents and Chemotherapy* 2010; 54: 397–404.
- 32 111. Lehman SM, Donlan RM. Bacteriophage-Mediated Control of a Two-Species Biofilm
33 Formed by Microorganisms Causing Catheter-Associated Urinary Tract Infections in
34 an In Vitro Urinary Catheter Model. *Antimicrobial Agents and Chemotherapy* 2015;
35 59: 1127–1137.
- 36 112. Melo LDR, Veiga P, Cerca N, et al. Development of a Phage Cocktail to Control
37 *Proteus mirabilis* Catheter-associated Urinary Tract Infections Bacterial Strains and
38 Culture Conditions. *Frontiers in Microbiology* 2016; 7: 1–12.
- 39 113. Nzakizwanayo J, Hanin A, Alves DR, et al. Bacteriophage can prevent encrustation
40 and blockage of urinary catheters by *Proteus mirabilis*. *Antimicrobial Agents and*
41 *Chemotherapy* 2016; 60: 1530–1536.
- 42 114. Milo S, Hathaway H, Nzakizwanayo J, et al. Prevention of encrustation and blockage
43 of urinary catheters by *Proteus mirabilis* via pH-triggered release of bacteriophage. *J*
44 *Mater Chem B* 2017; 5: 5403–5411.
- 45 115. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. *Nature*
46 *Reviews Microbiology* 2010; 8: 317–327.
- 47 116. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. *Bacteriophage* 2011; 1:
48 111–114.
- 49 117. Gu J, Liu X, Li Y, et al. A method for generation phage cocktail with great therapeutic
50 potential. *PLoS ONE*; 7. Epub ahead of print 2012. DOI:
51 10.1371/journal.pone.0031698.
- 52 118. Webber MA, Piddock LJ V. The importance of efflux pumps in bacterial antibiotic
53
54
55
56
57
58
59
60

- 1
2
3 resistance. *Journal of Antimicrobial Chemotherapy* 2003; 51: 9–11.
- 4 119. Holling N, Lednor D, Tsang S, et al. Elucidating the genetic basis of crystalline
5 biofilm formation in *Proteus mirabilis*. *Infection and Immunity* 2014; 82: 1616–1626.
- 6 120. Amaral L, Martins A, Molnar J, et al. Phenothiazines, bacterial efflux pumps and
7 targeting the macrophage for enhanced killing of intracellular XDRTB. *In Vivo* 2010;
8 24: 409–424.
- 9 121. Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial
10 biofilm formation. *Applied and Environmental Microbiology* 2008; 74: 7376–7382.
- 11 122. Nzakizwanayo J, Scavone P, Jamshidi S, et al. Fluoxetine and thioridazine inhibit
12 efflux and attenuate crystalline biofilm formation by *Proteus mirabilis*. *Scientific*
13 *Reports*; 7. Epub ahead of print 2017. DOI: 10.1038/s41598-017-12445-w.
- 14 123. Davies DG, Parsek MR, Pearson JP, et al. The involvement of cell-to-cell signals in
15 the development of a bacterial biofilm. *Science (New York, NY)* 1998; 280: 295–8.
- 16 124. Jones SM, Dang TT, Martinuzzi R. Use of quorum sensing antagonists to deter the
17 formation of crystalline *Proteus mirabilis* biofilms. *International Journal of*
18 *Antimicrobial Agents* 2009; 34: 360–364.
- 19 125. Younis KM, Usup G, Ahmad A. Secondary metabolites produced by marine
20 streptomycetes as antibiofilm and quorum-sensing inhibitor of uropathogen *Proteus*
21 *mirabilis*. *Environmental Science and Pollution Research* 2016; 23: 4756–4767.
- 22 126. Grover N, Plaks JG, Summers SR, et al. Acylase-containing polyurethane coatings
23 with anti-biofilm activity. *Biotechnology and Bioengineering* 2016; 113: 2535–2543.
- 24 127. Ivanova K, Fernandes MM, Francesko A, et al. Quorum-Quenching and Matrix-
25 Degrading Enzymes in Multilayer Coatings Synergistically Prevent Bacterial Biofilm
26 Formation on Urinary Catheters. *ACS Applied Materials and Interfaces* 2015; 7:
27 27066–27077.
- 28 128. Dave RN, Joshi HM, Venugopalan VP. Novel biocatalytic polymer-based
29 antimicrobial coatings as potential ureteral biomaterial: Preparation and in vitro
30 performance evaluation. *Antimicrobial Agents and Chemotherapy* 2011; 55: 845–853.
- 31 129. Thallinger B, Argirova M, Lesseva M, et al. Preventing microbial colonisation of
32 catheters: Antimicrobial and antibiofilm activities of cellobiose dehydrogenase.
33 *International Journal of Antimicrobial Agents* 2014; 44: 402–408.
- 34 130. Irwin NJ, McCoy CP, Jones DS, et al. Infection-responsive drug delivery from urinary
35 biomaterials controlled by a novel kinetic and thermodynamic approach.
36 *Pharmaceutical Research* 2013; 30: 857–865.
- 37 131. McCoy CP, Irwin NJ, Brady C, et al. Synthesis and release kinetics of polymerisable
38 ester drug conjugates: Towards pH-responsive infection-resistant urinary biomaterials.
39 *Tetrahedron Letters* 2013; 54: 2511–2514.
- 40 132. McCoy CP, Irwin NJ, Brady C, et al. An Infection-Responsive Approach to Reduce
41 Bacterial Adhesion in Urinary Biomaterials. *Molecular Pharmaceutics* 2016; 13:
42 2817–2822.
- 43 133. Francesko A, Fernandes MM, Ivanova K, et al. Bacteria-responsive multilayer
44 coatings comprising polycationic nanospheres for bacteria biofilm prevention on
45 urinary catheters. *Acta Biomaterialia* 2016; 33: 203–212.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



20 Figure 1: Flowchart showing the sequential encrustation and blockage of an indwelling urinary catheter
21 following infection by *Proteus mirabilis*.

22 154x60mm (96 x 96 DPI)




Figure 2: Multi-inflation-lumen catheters able to cause debridement of multispecies *P. mirabilis* and *E. coli* biofilms in situ. Cross sectional images of A) control catheter (no inflation), B) first inflation after 30 hours of biofilm growth, C) second inflation after 24 hours biofilm regrowth. D) Sections from which the cross sections were obtained: i) bottom, ii) middle, iii) top, and iv) distal tip. Scale bars indicate 1 mm. Reprinted from [82]. © 2016, with permission from Elsevier.

137x120mm (300 x 300 DPI)






Figure 3: Assessment of a hydrogel-impregnated supramolecular Eu(III)-based pH-responsive "on-off" sensor for CAUTI. A) "on" (before addition of urease), B) "off" (200 minutes after addition of urease) states of the hydrogel, when irradiated at $\lambda_{\text{max}} = 254$ nm. C) Excitation spectra of the swollen Eu-based hydrogel, before and 200 minutes after the addition of urease (0.5 U), measured in an aqueous solution of urea (2.3×10^{-3} M) at 295 K. Adapted with permission from [90]. © 2016 American Chemical Society.

224x106mm (96 x 96 DPI)



23 Figure 4: Fluorescence microscopy images of PHA surfaces treated with oxygen plasma and incubated with
24 carrying concentrations (plaque forming units per millilitre (PFU/ml)) of T4 bacteriophage. Top row:
25 characterisation of immobilised bacteriophage on PHA. Bottom row: Stained *E. coli* host cells in stationary
26 phase, captured on surfaces with immobilised bacteriophage. A, E) Control films (no bacteriophage). B, F)
27 Films prepared with 2×10^8 PFU/ml. C, G) Films prepared with 2×10^9 PFU/ml. D, H) Films prepared with $2 \times$
28 10^{10} PFU/ml. Both phage and bacterial cells were stained using SYBR green, 1 hour post-immobilisation and
29 prior to exposure, respectively. Reprinted with permission from [108]. © 2016 American Chemical Society.

30 154x74mm (300 x 300 DPI)



23 Figure 5: Effect of hyaluronic acid coated AC nanospheres (HA/ACNSS) on *P.aeruginosa* biofilm
24 formation within the shaft of a foley catheter after 7 hours incubation (bottom), compared to the uncoated
25 control catheter (top). Fluorescent microscopy images are 20 x mag with scale bars set at 100 μ m.
26 Reprinted from [133]. © 2016, with permission from Elsevier.

27 129x63mm (113 x 113 DPI)